根据批复，中国证监会同意本公司向专业投资者公开发行面值总额不超过人民币60亿元科技创新公司债 券的注册申请。该批复自同意注册之日起24个月内有效，本公司在注册有效期内可分期发行科技创新公 司债券。 格隆汇2月26日丨复星医药(600196.SH)公布，公司收到中国证券监督管理委员会（以下简称"中国证监 会"）出具的《关于同意上海复星医药（集团）股份有限公司向专业投资者公开发行科技创新公司债券 注册的批复》（证监许可〔2026〕298号）（以下简称"批复"）。 ...

Core Viewpoint - The article discusses the financial struggles and strategic asset sales of Fosun Group, particularly focusing on its investment in Shede Liquor, highlighting the concept of "sacrifice for gain" in the context of business survival and adaptation to market conditions [4][7][10]. Group 1: Financial Performance and Challenges - In January 2026, the parent company of Shede Liquor, Yuyuan Group, announced an expected net loss of 4.8 billion yuan for 2025, marking its first annual loss since its listing in 1992 [4][10]. - The losses are attributed to pressures from a declining real estate market and weak consumer demand, prompting a significant asset impairment and inventory reduction strategy [4][10]. - In 2025, Shede Liquor reported a revenue of 3.1 billion yuan and a net profit of 470 million yuan, which, while modest compared to industry leaders, positions it as the second most profitable entity within Fosun's portfolio [37][39]. Group 2: Strategic Asset Sales - Fosun Group has sold over 80 billion yuan worth of assets in recent years, including stakes in various companies and properties, to improve liquidity amid tightening regulations and financial pressures [7][29]. - The company has divested from several businesses, including Qingdao Beer and Shunxin Agriculture, while maintaining and even increasing its stake in Shede Liquor, indicating its strategic importance [31][32]. - The asset sales are part of a broader strategy to navigate liquidity challenges, with Fosun's CEO emphasizing that "a sellable enterprise is a good enterprise" [29][30]. Group 3: Market Position and Future Outlook - Shede Liquor, despite its challenges, has maintained a strong market presence and is seen as a key asset for Fosun, especially as it navigates through a difficult industry landscape [38][41]. - The company has proactively reduced inventory and adjusted its market strategy, which has allowed it to avoid the severe profit declines experienced by many competitors in the industry [40][41]. - The increase in Shede Liquor's dividend payout ratio from 25.77% in 2020 to 40.9% in 2024 reflects its importance as a cash-generating asset for Fosun, even as overall profits have declined [39][40].

Core Viewpoint - The diagnostic reagent industry in China is experiencing fluctuations in market size due to the impact of COVID-19, with a projected recovery and growth expected by 2025, reaching a market size of 140 billion yuan, an 8% increase year-on-year [6][7]. Industry Overview - Diagnostic reagents are essential tools in medicine and biology for detecting diseases, infections, and other medical conditions through interactions with biological samples [4][6]. - The market is primarily dominated by in vitro diagnostic reagents, while in vivo diagnostics remain relatively small [6]. Market Size and Trends - The market for in vitro diagnostic reagents in China has shown an upward trend since 2015, with rapid growth from 2020 to 2022 due to the pandemic, but a 14% decline in 2023 due to reduced demand for COVID-19 diagnostic reagents [6][7]. - The market is expected to recover in 2024, with projections indicating a market size of 140 billion yuan by 2025, reflecting an 8% year-on-year growth [6][7]. Competitive Landscape - The diagnostic reagent market includes both domestic companies like Mindray Medical, Antu Bio, and Wanfu Bio, and international firms such as Roche Diagnostics and Abbott, all competing for market share [8]. - Domestic companies are noted for their strong R&D capabilities and significant market presence [8]. Industry Development Stages - The diagnostic reagent industry in China has progressed through four stages: nascent, initial, extensive development, and rapid growth, with significant advancements in technology and regulatory improvements since the 21st century [5]. Industry Chain - The industry chain consists of upstream raw materials (diagnostic enzymes, antigens, antibodies, etc.), the midstream diagnostic reagent production, and downstream applications in medical institutions and third-party diagnostic organizations [6]. Market Segmentation - The in vitro diagnostic reagent market is segmented, with immunodiagnostic reagents holding a 32% market share, followed by molecular diagnostic reagents at 19%, and biochemical diagnostic reagents at 18% [7]. Future Trends - The industry is expected to focus on high-end product upgrades, with companies increasing R&D investments to enhance product value amidst price pressures from centralized procurement [9]. - There is a trend towards market penetration in lower-tier cities and global expansion, with domestic products entering emerging markets in Southeast Asia and Africa [10]. - The industry is evolving towards a model centered on clinical value and personalized medicine, integrating diagnostic solutions with treatment recommendations [11].

Policy Developments - Shandong Province held a meeting on February 25, 2026, to address corruption and misconduct in the healthcare sector, emphasizing the need for a coordinated effort to safeguard medical insurance funds and promote orderly development in healthcare [1] Drug and Device Approvals - Kanghong Pharmaceutical received approval from the National Medical Products Administration for clinical trials of KHN707 tablets for insomnia, a class 1 innovative drug [2] - Fosun Pharma's subsidiary received approval for clinical trials of Rumaine® (generic name: Luwomeitini tablets) for advanced non-small cell lung cancer, with global sales of MEK1/2 inhibitors projected to reach approximately $2.068 billion in 2024 [3] - China Pharmaceutical announced that its subsidiary received a drug registration certificate for injectable fosfomycin, aimed at treating acute bacterial skin and soft tissue infections [4] - Huyou Pharmaceutical received FDA approval for its new drug applications for Etoposide injection and Fluorouracil injection, enabling sales in the U.S. market [5] - Kangfang Biotech's application for the monoclonal antibody AK120 was accepted for review by the National Medical Products Administration [6] Industry Developments - Junshi Bioscience and Deqi Pharmaceuticals entered a strategic collaboration to explore the combined treatment potential of JS207 and ATG-037 for cancer patients in mainland China [8] - Illumina announced an 18-month innovation upgrade roadmap for the NovaSeq X sequencer, enhancing its capabilities and productivity [9] Capital Market Activities - Sainuo Medical announced a share repurchase plan with a total amount between 15 million and 30 million yuan, aimed at employee stock ownership plans or equity incentives [10] Financial Data - United Imaging reported a net profit of 1.888 billion yuan for 2025, a year-on-year increase of 49.60%, driven by new product launches and growth in overseas business [11] - Xiansheng Pharmaceutical projected a revenue of approximately 7.7 billion to 7.8 billion yuan for the 2025 fiscal year, with a net profit increase of 80.1% to 93.9% [12] - Sainuo Medical reported a net profit of 47.29 million yuan for 2025, a significant increase of 3,057.05% year-on-year, attributed to revenue growth and cost management [13]

| 晨会聚焦 | | --- | | 一、财信研究观点 | | 【市场策略】大盘放量上涨，资源股持续发酵 | | 【基金研究】基金数据日跟踪 | | 【债券研究】债券市场综述 | | 二、重要财经资讯 | | 【宏观经济】香港财政司发表 2026 至 2027 财政年度政府财政预算案 | | 【宏观经济】美国总统特朗普在国会发表其第二任期的首次国情咨文演 | | 讲 | | 【宏观经济】央行开展 亿元 操作 6000 MLF | | 【财经要闻】2026 中关村论坛年会将于 3 月 25 日至 29 日在京举办 | | 【财经要闻】2026 年 月月末全国乘用车行业库存 万辆 1 357 | | 三、行业及公司动态 | | 【行业动态】上海五部门：非沪籍外环内购房社保年限降至 1 年，缴满 3 | | 年可增购 1 套 | | 【公司跟踪】复星医药（600196.SH）：芦沃美替尼片的临床试验申请获 | | 得批准 | | 【公司跟踪】影石创新（688775.SH）发布 年业绩快报：归母净利 2025 | | 润同比-3.08% | | 【公司跟踪】苏泊尔（002032.SZ）发布 2025 年业绩快报：归母 ...

（原标题：A股公告精选 | 中芯国际(688981.SH)拟购中芯北方49%股权 *ST岩石可能被终止上市） 今日聚焦 1、ST西发：收到法院对预重整延期决定书 ST西发2月25日公告，2023年7月25日，公司收到西藏自治区拉萨市中级人民法院送达的《决定书》，经债权人申请，拉萨中院决定对公司进行预 重整，并指定上海市锦天城律师事务所担任公司预重整临时管理人，具体负责开展各项工作。公司于2026年2月25日收到拉萨中院决定书，主要内 容如下："本院认为，临时管理人提出西藏发展因历史问题情况复杂，部分债务涉及历史遗留问题提出延期，其理由正当。为有效维护企业运营价 值，维护债权人合法权益，提高重整效率和效果，决定对西藏发展预重整延期1个月，即自2026年2月26日延长至2026年3月25日。" 2、方正证券：减持计划实施期限届满 中国信达未减持公司股份 方正证券2月25日公告，公司股东中国信达于2025年11月26日至2026年2月25日期间未减持公司股份，原计划减持不超过8232万股，约占公司总股 本的1.00%。截至2026年2月25日，减持计划实施期限届满，中国信达未减持公司股份。 3、川金诺：市场传闻称美 ...

近来复星系动作频频，接连减持山河药辅、重庆农商行进行套现。 复星集团去年上半年营收、净利双降；旗下公司最新业绩显著分化，复星医药、复兴保德信人寿等业绩向好，而豫园股份上市以来首次出现亏损，预计去 年将大幅亏损48亿元。 山河药辅于本月24日发布公告称，公司持股5%以上股东复星医药的股份减持计划已实施完毕。复星医药原计划在2025年11月24日至2026年2月21日期间， 以集中竞价交易或大宗交易方式合计减持山河药辅不超过697.87万股股份，占其总股本(扣除回购股份182.55万股)的3%。本次减持完成后，复星医药的持 股比例从9.3%降至8.3%，仍为其第二大股东。数据还显示，自2018年至2025年上半年，复星医药减持山河药辅共计9次，累计套现至少1.5亿元。 2月初，港交所发布的公告显示，复星系核心人物郭广昌通过二级市场减持重庆农商行H股472.6万股，累计套现约2882万港元(折合人民币约2545万元)。 本次减持后，郭广昌对重庆农商行的持股比例由13.56%降至12.98%，仍为公司前十大股东。可以看到的是，郭广昌此次减持适逢重庆农商行H股股价处于 阶段性高位。 以上动作或许与复星系此前提出的"聚焦 ...

北京商报讯（记者 丁宁）2月25日晚间，复星医药（600196）发布公告称，公司控股子公司上海复星医 药产业发展有限公司（以下简称"复星医药产业"）收到国家药品监督管理局关于同意复迈宁（通用名： 芦沃美替尼片）联合安罗替尼用于鼠类肉瘤病毒癌基因（KRAS）突变的晚期非小细胞肺癌（NSCLC） 患者开展临床试验的批准。复星医药产业拟于条件具备后于中国境内开展该药品的Ⅱ期临床试验。 公告显示，该药品已于中国境内上市并获批两项适应症，包括用于治疗朗格汉斯细胞组织细胞增生症 （LCH）和组织细胞肿瘤成人患者；以及2岁及2岁以上伴有症状、无法手术的丛状神经纤维瘤（PN） 的Ⅰ型神经纤维瘤病（NF1）儿童及青少年患者。 ...

Group 1: Financial Performance Highlights - Lante Optics achieved a revenue of 1.536 billion yuan in 2025, a year-on-year increase of 48.52%, with a net profit of 388 million yuan, up 76.09% [1] - United Imaging reported a revenue of 13.82 billion yuan for 2025, reflecting a 34.18% year-on-year growth, and a net profit of 1.888 billion yuan, up 49.60% [2] - Hengxuan Technology's revenue reached 3.525 billion yuan, an 8.02% increase, with a net profit of 588 million yuan, up 27.75% [3] - Nanya New Materials reported a significant net profit increase of 378.65%, reaching 241 million yuan, with revenue of 5.228 billion yuan, up 55.52% [4] - Yancoal Australia, a subsidiary of Yancoal Energy, reported a revenue of 5.949 billion AUD and a net profit of 4.4 billion AUD for 2025 [5] - Hanlan Co. reported a revenue of 10.467 billion yuan, a 13.04% increase, but a net profit decline of 9.59% to 592 million yuan [10][11] - Transsion Holdings experienced a revenue decline of 4.50% to 65.623 billion yuan, with a net profit drop of 53.43% to 2.584 billion yuan [14] - Huachuang Technology achieved a revenue of 628 million yuan, a 2.78% increase, with a net profit of 42.678 million yuan, up 89.45% [21] - Aiko Optoelectronics reported a revenue of 440.311 million yuan, a 77.36% increase, with a net profit of 64.0919 million yuan, up 307.63% [34] - Chip Microelectronics achieved a revenue of 1.408 billion yuan, a 47.61% increase, with a net profit of 290 million yuan, up 80.42% [35] - Shenkong Co. reported a revenue of 443 million yuan, a 46.26% increase, with a net profit of 101 million yuan, up 146.54% [36] - Qinda Environmental reported a revenue of 2.042 billion yuan, a 55.42% increase, with a net profit of 181 million yuan, up 94.62% [39] Group 2: Corporate Developments - Huilong New Materials announced that its actual controller is planning a significant matter that may lead to a change in company control, resulting in a stock suspension [6] - Fangzheng Securities disclosed that its shareholder China Cinda did not reduce its shareholding as planned during the designated period [7] - Lingyi Technology plans to invest 20 million yuan in a partnership with several investment firms [8] - Longbai Group's subsidiary has partially resumed production after a safety incident [9] - Fuda Co. plans to reduce its repurchased shares by up to 1% through centralized bidding [13] - Fuxing Pharmaceutical's subsidiary received approval for clinical trials of a new drug for lung cancer [15] - Beixin Road and Bridge won a bid for a highway reconstruction project worth 751 million yuan [16] - Songsheng Co. established a joint venture with a registered capital of 30 million yuan, focusing on digital energy products [17] - Moxinlin reported a revenue of 577 million yuan, a 20.98% increase, with a net profit of 55.8745 million yuan, up 22.69% [18] - Zhuhai Beer reported a revenue of 5.878 billion yuan, a 2.56% increase, with a net profit of 903 million yuan, up 11.42% [24] - Honghua Digital reported a revenue of 2.308 billion yuan, a 28.90% increase, with a net profit of 529 million yuan, up 27.63% [25] - Xinfeng Pharmaceutical received FDA approval for two injectable drugs [26] - Jiazhe New Energy's project for green hydrogen production received regulatory approval [27] - Chip Microelectronics reported a revenue of 5.24 billion yuan, a 29.48% increase, with a net profit of 302 million yuan, up 36.1% [28] - Debang Co. completed the cash settlement process for its delisting [29] - Xingfu Electronics reported a revenue of 1.475 billion yuan, a 29.72% increase, with a net profit of 208 million yuan, up 30.37% [30] - Longda Food announced the resignation of its general manager due to work adjustments [31] - Bohai Chemical reported that some fundraising projects have commenced production [32] - Shengke Communication reported a net loss of 150 million yuan for 2025 [33] - Jin Cheng Pharmaceutical's subsidiaries received drug registration certificates for two products [37] - Jinpu Titanium Industry announced the resumption of production at its subsidiary [38] - Zhigao Electric's subsidiary won a bid for a project worth 182 million yuan [40]

根据公告，芦沃美替尼片为MEK1/2选择性抑制剂。目前，该药品已于中国境内（不含港、澳、台地 区）上市并获批两项适应症，包括用于治疗朗格汉斯细胞组织细胞增生症（LCH）和组织细胞肿瘤成人 患者以及2岁及2岁以上伴有症状、无法手术的丛状神经纤维瘤（PN）的Ⅰ型神经纤维瘤病（NF1）儿 童及青少年患者。 北京商报讯（记者 王寅浩 宋雨盈）2月25日，复星医药发布公告称，公司控股子公司上海复星医药产业 发展有限公司收到国家药品监督管理局关于同意复迈宁®（通用名：芦沃美替尼片）联合安罗替尼用于 鼠类肉瘤病毒癌基因（KRAS）突变的晚期非小细胞肺癌（NSCLC）患者开展临床试验的批准。复星医 药产业拟于条件具备后开展该药品的Ⅱ期临床试验。 ...